Skip to main content

TRASIS closes a record year in 2022 with a +50% growth in sales. It invests for its future via the acquisition of ERAS LABO (Grenoble, France), a co-investment in the Belgian start-up ABSCINT (Ganshoren, Belgium) and adds 5,000m² to its current infrastructure.

Ans, February 20, 2023. Trasis is increasingly establishing itself in the Liège region as a key player in the life sciences. “At the end of 2022, when our sales grew by 50%, we recruited around 100 new employees. We currently have 278 employees, 240 of whom are located in Ans (Liege). Four years ago we were 57. We expect to be around 600 in 7 years“, says Jean-Luc Morelle, co-founder and CTO of Trasis.

Trasis is a unique company in the field of radiochemistry and nuclear medicine: it brings together all the skills in-house and provides the equipment needed for the daily production of radiopharmaceuticals used in particular in PET-Scan. Its customers, research centers, pharmaceutical companies and hospitals are served by a company that takes responsibility for a complete chain of supply and expertise.

TRASIS strengthens its position through an acquiition and an investment in two innovative companies

TRASIS acquires the company (Eras Labo) and co-invests in a Belgian startup (Abscint). ERAS LABO (25 employees) is a company specialized in contract chemistry, covering a wide range of activities from research and development to routine production.
development to routine production. The company has 1,000m² of laboratory space in Saint-Nazaire-les-Eymes (Grenoble, France). With this acquisition, Trasis secures part of its supply chain and seizes a sought-after opportunity for diversification within and outside the radiopharmaceutical sector. ABSCINT (6 employees, Ganshoren, Belgium) is a clinical stage molecular imaging company that develops radiopharmaceutical diagnostics to guide patients and physicians to the right treatment at the right time. With these new investments, Trasis aims to reinforce its commitment to innovation and to participate in the advancement of the radiopharmaceutical industry. This is in addition to previous investments, such as the launch of a subsidiary in the United States and spending on R&D, which represents approximately 11% of its sales.

At Trasis, we are committed to accelerating the manufacturing of products that our partners need. We also support and co-invest in the radiopharmaceutical and digital imaging value chain while supporting the development of new start-ups. We still plan to recruit more than 70 people in 2023 to support our growth. The most sought-after profiles are engineers, computer scientists, production operators and laboratory technologists,” says Gauthier Philippart, co-founder and CEO of Trasis.

A new building in Ans, scheduled for completion in November 2023

Trasis promotes well-being at work and local employment: 80% of Trasis employees come from the Liege region. In November 2023, a new 5,000 m² workspace will be completed in Ans (Liège). A new 60,000 m² site has just been acquired in the same region. Trasis is already investing in its future with an unwavering determination to contribute to the creation of local jobs and to develop its local roots in order to conquer new market segments. Trasis and its teams are proud to participate in the war against cancer and other diseases.


TRASIS, a world leader in nuclear medicine, designs and manufactures equipment for the diagnosis and treatment of cancer and neurodegenerative diseases: a technology in high demand and already present in 58 countries. In 2022, Trasis has recorded a growth in turnover of more than 50% compared to 2021. Trasis employs about 280 people in Belgium, France, USA and other countries and exports 95% of its sales. Trasis is the 2022 winner of the Wallonia Golden Export Award.

Press/media contact: Frédéric Matriche – Pixel Prod +32(0)479 29 04 47 – –